As the 2024 elections approach, high prescription drug prices are becoming a central issue, with both presidential candidates, Donald Trump and Kamala Harris, acknowledging the need for reform. Despite recent Medicare negotiations that have cut prices for several drugs, congressional Republicans are pushing to repeal these provisions, arguing that they stifle innovation and harm the pharmaceutical industry. A RAND Corporation study highlighted that Americans pay significantly more for brand-name drugs compared to other developed nations, prompting calls for change from both sides of the political spectrum. However, the GOP's focus on repealing drug pricing negotiations, as voiced by Rep. Buddy Carter and Sen. Thom Tillis, contrasts with Trump's populist stance against Big Pharma. Ultimately, the future of drug pricing policies in the U.S. may hinge on the outcome of the elections, with potential shifts in how Medicare negotiates drug costs. Experts predict that while changes are likely, they may not be as drastic as some advocates hope.